Irish biotech group Elan is to suspend trading in its shares for two days while the US Food and Drug Administration advisory committee meets to decide whether its multiple sclerosis drug Tysabri can return to the full market.
In a statement yesterday, Elan said the trading of its securities on the Irish Stock Exchange, the London Stock Exchange and the New York Stock Exchange will be suspended from March 7th for two days while the FDA meets to review Tysabri.
Biogen Idec and Elan removed Tysabri from the US market in February of 2005 after two patients developed a rare brain disorder and one died.